HHS, CVS, Walgreens get behind Abbott's coronavirus test

HHS has ordered 1,200 of Abbott's portable testing instruments and more than 30,000 of the point-of-care, quick-turnaround tests. The big retail pharmacy chains are also adopting the product as they expand drive-thru testing.

By Maria Rachal • April 8, 2020

OraSure wins BARDA contract for in-home coronavirus self-test

The test could become the first authorized by FDA for use at home to detect the virus, but its development won't likely be complete for at least another four to six months.

By Susan Kelly • April 8, 2020

Explore the Trendline➔

Top 5 stories from MedTech Dive

From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.

By MedTech Dive staff

White House official urges caution before assuming coronavirus antibody test accuracy

The FDA last month made it easier for companies to quickly develop serology tests. But the Trump administration’s coordinator for coronavirus diagnostic testing warned against overreliance on the tests before they are validated.

By Greg Slabodkin • April 7, 2020

Commercial labs push for piece of $100B coronavirus relief

The trade group representing LabCorp and Quest wants HHS to allocate CARES Act money for expenses or lost revenue related to COVID-19. But there's strong competition from healthcare providers also hurting financially.

By Greg Slabodkin • April 6, 2020

FDA authorizes Cellex coronavirus antibodies test

It's the first test of its kind to obtain FDA emergency use authorization, although other companies are working to roll out serological tests for the virus.

By Maria Rachal • April 3, 2020

Medtechs navigate new normal as FDA shifts priorities to coronavirus

Companies are working to get diagnostics, respiratory devices and PPE to market amid rapidly evolving guidance from FDA. The agency's coronavirus-era operations may also impact work for device makers in other parts of the sector.

By Maria Rachal • April 3, 2020

FDA clears Sectra's digital pathology module for primary diagnostics as US market heats up

The clearance will intensify competition in the space initially monopolized by Philips, with big medtechs like Roche aiming to enter. The ability to review images from anywhere may be critical amid the coronavirus pandemic.

By Nick Paul Taylor • April 2, 2020

BD rolls out test to detect coronavirus antibodies

Some experts point to serology tests, which may help identify people who have immunity, as a key tool in U.S. management of COVID-19 going forward. The BD test has already seen significant use in China.

By Susan Kelly • April 1, 2020

Abbott touts speed, scale of POC coronavirus test

The point-of-care diagnostic may detect the pathogen in as little as five minutes, processed on the same machines already in doctors' offices and clinics. Former FDA chief Scott Gottlieb called it a "game changer."

By Maria Rachal • March 30, 2020

Small PAMA victory in aid package, but labs remain in 'untenable situation'

Quest, LabCorp and others scaling up U.S. coronavirus testing will see a delay in Medicare payment reductions as part of the CARES Act signed into law Friday, but industry argues labs have been shortchanged on emergency funds.

By Maria Rachal • Updated March 27, 2020

UnitedHealth says self-swabbing study spurred FDA coronavirus policy change

The agency now allows onsite, self-collection of samples, after a nearly 500-patient study found self-administered tests about as accurate as those carried out by clinicians.

By Nick Paul Taylor • March 26, 2020

Tracking the impact of coronavirus on the medtech industry

Among the latest: As COVID-19 test sales boom, Hologic thinks its revenues this quarter may be 60% higher than last year's.

By Nami Sumida • Updated Sept. 11, 2020

Clinical labs, White House tell different stories on testing backlog

The American Clinical Laboratory Association said without sufficient funds from the federal government, commercial labs might be forced to "retrench rather than keep building the capacity that is needed."

By Greg Slabodkin • March 24, 2020

CDRH pushes out response due date extensions, teleconference policy by at least a month

Less than two weeks after FDA wrote to industry extending deadlines for premarket application responses and warning of disruptions to in-person meetings, the agency lengthened those coronavirus-era changes.

By Maria Rachal • Updated April 6, 2020

MedTech Europe calls for delay of MDR until coronavirus crisis passes

The trade group argued industry is “working relentlessly” on getting devices to healthcare professionals fighting COVID-19, while simultaneously trying to maintain supply of other products, leaving little bandwidth to focus on new regs.

By Nick Paul Taylor • March 24, 2020

Cepheid wins 1st FDA nod for point-of-care coronavirus test

The Sunnyvale, California-based molecular diagnostics company said there are currently close to 5,000 of its systems in the U.S. that can run its 45-minute test in hospitals.

By Greg Slabodkin • March 23, 2020

Lab industry 'alarmed,' says Senate stimulus bill fails to back testing ramp-up

Without $5 billion in assistance, the American Clinical Laboratory Association contends commercial labs are "being set up to perform COVID-19 testing at a loss." A Senate vote could come Monday.

By Greg Slabodkin • Updated March 23, 2020

Direct-to-consumer companies wade into coronavirus testing to fill gap

Everlywell said Monday it planned to donate its store of COVID-19 tests to hospitals, following guidance from FDA warning consumers of fraudulent at-home tests.

By Rebecca Pifer • Updated March 23, 2020

Diagnostic, device makers scrambling as COVID-19 sweeps US

What began as a potential Q1 headwind for medtechs manufacturing in China has quickly turned into a global crisis with unprecedented challenges and opportunities as the sector grapples with the pandemic.

March 20, 2020

Exact Sciences pulls 2020 sales guidance amid coronavirus uncertainty

Shares in the molecular diagnostics company rose 32% Thursday, suggesting investors are betting use of the firm's flagship colorectal cancer screening test will be relatively immune from the pandemic.

By Nick Paul Taylor • March 20, 2020

CMS urges hospitals to put off elective procedures

The guidelines suggest three tiers, with procedures like hip and knee replacements falling into the "consider postponing" category.

By Shannon Muchmore • March 19, 2020

Abbott latest to get FDA emergency use nod for coronavirus test

It's the seventh medtech to win the agency's emergency use authorization within the last week as the Trump administration attempts to leverage the private sector, including commercial labs, to boost the nation's testing capacity.

By Greg Slabodkin • March 19, 2020

New notified bodies trickle in ahead of looming MDR start date

The 12th notified body authorized for MDR work, and the first from Hungary, was listed in the NANDO database Friday: CE Certiso.

By Nick Paul Taylor • Updated March 20, 2020

FDA pulls plug on routine US inspections

The move to protect staff and acknowledge industry worries about outside visitors amid coronavirus comes a week after the agency said it would postpone nearly all overseas inspections through April.

By Nick Paul Taylor • March 19, 2020

How an 'overwhelmed' Buffalo lab facing coronavirus supply shortage signals nationwide struggles

The Western New York regional public health lab is a microcosm of the insufficient swab and reagent stocks labs face as they attempt to confirm COVID-19 cases and gauge the scope of their region's outbreak.

By Greg Slabodkin • March 18, 2020